Synthesis and antitumor activity of novel N-substituted carbazole imidazolium salt derivatives

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Liu, Lan Xiang ^a,d   Wang, Xue Quan ^a   Zhou, Bei ^a   Yang, Li Juan ^c   Li, Yan ^b   Zhang, Hong Bin ^a   Yang, Xiao Dong ^a  

^a YUNNAN UNIVERSITY   (China)

^b KUNMING INSTITUTE OF BOTANY   (China)

^c YUNNAN MINZU UNIVERSITY   (China)

^d RESEARCH INSTITUTE OF FORESTRY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBAZOLE; CARBAZOLE DERIVATIVE; IMIDAZOLE; IMIDAZOLE DERIVATIVE;

APOPTOSIS; CELL CYCLE CHECKPOINT; CELL DEATH; CHEMISTRY; DRUG EFFECTS; HUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAZOLES; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMIDAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84939815939     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13101     Document Type: Article

References (32)

1. Schmidt, A. W., Reddy, K. R., Knölker, H. J. Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids. Chem. Rev. 112, 3193-3328 (2012).
2. Guszyska, A. Biological potential of carbazole derivatives. Eur. J. Med. Chem. 94, 405-426 (2015).
3. Knolker, H. J., Reddy, K. R. in The alkaloids. Chemistry and biology, vol. 65 (ed Cordell, G. A.) Ch. 4, 181-193 (Academic Press, 2008).
4. Knölker, H. J., Reddy, K. R. Isolation and synthesis of biologically active carbazole alkaloids. Chem. Rev. 102, 4303-4427 (2002).
5. Knölker, H. J. Transition metal complexes in organic synthesis. Part 70: Synthesis of biologically active carbazole alkaloids using organometallic chemistry. Curr. Org. Synth. 1, 309-331 (2004).
6. Choi, T. A. et al. Synthesis and activity of carbazole derivatives against Mycobacterium tuberculosis. Chem Med Chem 1, 812-815 (2006).
7. Choi, T. A. et al. Transition metal complexes in organic synthesis. Part 70: Synthesis of biologically active carbazole alkaloids using organometallic chemistry. Med. Chem. Res. 17, 374-385 (2008).
8. Forke, R., Jäger, A., Knolker, H. J. First total synthesis of clausine L and pityriazole, a metabolite of the human pathogenic yeast Malassezia furfur. Org. Biomol. Chem. 6, 2481-2483 (2008).
9. Hou, S. et al. Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6. J. Med. Chem. 57, 6342-6353 (2014).
10. Shaikh, M. S. et al. Current perspective of natural alkaloid carbazole and its derivatives as antitumor agents. Anti-Cancer Agents Med. Chem. doi: 10.2174/1871520615666150113105405 (2015).
11. Christian, A., Martine, D. Antitumor carbazoles. Anti-Cancer Agents Med. Chem. 7, 247-267 (2007).
12. Ito, C. et al. Chemical constituents of Glycosmis arborea: Three new carbazole alkaloids and their biological activity. J. Nat. Prod. 67, 1488-1491 (2004).
13. Songsiang, U., Thongthoom, T., Boonyarat, C., Yenjai, C. Claurailas A-D, cytotoxic carbazole alkaloids from the roots of Clausena harmandiana. J. Nat. Prod. 74, 208-212 (2011).
14. Zhang, L., Peng, X. M., Damu, G. L. V., Geng, R. X., Zhou, C. H. Comprehensive review in current developments of imidazolebased medicinal chemistry. Med. Res. Rev. 34, 340-437 (2014).
15. Riduan, S. N., Zhang, Y. Imidazolium salts and their polymeric materials for biological applications. Chem. Soc. Rev. 42, 9055-9070 (2013).
16. Ramos, L. M. et al. The biginelli reaction with an imidazolium-tagged recyclable iron catalyst: Kinetics, mechanism, and antitumoral activity. Chem. Eur. J. 19, 4156-4168 (2013).
17. Fortuna, C. G., Barresi, V., Berellini, G., Musumarra, G. Design and synthesis of trans 2-(furan-2-yl)vinyl heteroaromatic iodides with antitumour activity. Bioorg. Med. Chem. 16, 4150-4159 (2008).
18. Cui, B., Zheng, B. L., He, K., Zheng, Q. Y. Imidazole alkaloids from Lepidium meyenii. J. Nat. Prod. 66, 1101-1103 (2003).
19. Xu, X. L. et al. Synthesis and antitumor activity of novel 2-substituted indoline imidazolium salt derivatives. Org. Biomol. Chem. 13, 1550-1557 (2015).
20. Sun, C. J. et al. Design, synthesis and antitumor activity of novel 8-substituted 2,3,5,6-tetrahydrobenzo[1,2-b:4,5-b'] difuran imidazolium salt derivatives. RSC Adv. 4, 16312-16319 (2014).
21. Wang, X. Q. et al. Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents. Eur. J. Med. Chem. 62, 111-121 (2013).
22. Liu, L. X. et al. Synthesis and antitumor activities of novel dibenzo [b, d] furane imidazole hybrid compounds. Eur. J. Med. Chem. 66, 423-437 (2013).
23. Zeng, X. H., Yang, X. D., Zhang, Y. L., Qing, C., Zhang, H. B. Synthesis and antitumor activity of 1-mesityl-3-(2-naphthoylmethano)-1H-imidazolium bromide. Bioorg. Med. Chem. Lett. 2010, 20, 1844-1847.
24. Fortin, S., Berube, G. Advances in the development of hybrid anticancer drugs. Expert Opin. Drug Dis. 8, 1029-1047 (2013).
25. Morphy, B. Hybrid molecules with a dual mode of action: dream or reality Acc. Chem. Res. 41, 69-77 (2007).
26. Viegas Jnr, C., Danuello, A., Bolzani, V. S., Barreiro, E. J., Fraga, C. A. M. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr. Med. Chem. 14, 1829-1852 (2007).
27. Vilanova, C. et al. Design and synthesis of pironetin analogue/colchicine hybrids and study of their cytotoxic activity and mechanisms of interaction with tubulin. J. Med. Chem. 57, 10391-10403 (2014).
28. Li, L. et al. Synthesis, in vitro and in vivo antitumor activity of scopoletin-cinnamic acid hybrids. Eur. J. Med. Chem. 93, 300-307 (2015).
29. Wei, Z. L. et al. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: Design, synthesis, and effects on cardiomyocyte differentiation. J. Am. Chem. Soc. 126, 16714-16715 (2004).
30. Liu, W. et al. Two mixed-NH3/amine platinum (II) anticancer complexes featuring a dichloroacetate moiety in the leaving group. Sci. Rep. 3, 24641 (2013).
31. Ranke, J. et al. Design of sustainable chemical products-the example of ionic liquids. Chem. Rev. 107, 2183-2206 (2007).
32. Löbrich, M., Jeggo, P. A. The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat. Rev. Cancer 7, 861-869 (2007).